Mineralys Therapeutics, Inc., a biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone, announced today that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference. The conference will take place in Las Vegas on May 14-16, 2024.
The fireside chat featuring Mineralys Therapeutics will be held on Wednesday, May 15, 2024, at 5:00pm PDT. A live webcast of the event will be available on the company’s website at www.mineralystx.com and can be accessed under “News and Events” in the Investor Relations section. Additionally, a replay of the fireside chat will be accessible on the website for approximately 90 days after the event.
Mineralys Therapeutics is dedicated to developing innovative treatments for cardiorenal conditions affected by dysregulated aldosterone. Their lead product candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor designed to address these conditions. Based in Radnor, Pennsylvania, the company was founded by Catalys Pacific and is committed to improving patient outcomes through cutting-edge research and development. For more information about Mineralys Therapeutics and their work towards treating cardiorenal conditions affected by dysregulated aldosterone, visit their website at https://mineralystx.com or follow them on LinkedIn and Twitter.
For media relations inquiries, please contact Tom Weible at Elixir Health Public Relations by phone at (1) 515-707-9678 or email at tweible@elixirhealthpr.com